SalioGen Therapeutics

Yesterday, SalioGen teamed up with Life Science Cares Boston to pack nearly 200 backpacks with supplies for high school students experiencing homelessness and poverty and donated them to School on Wheels of Massachusetts. We’re grateful for the opportunity to make a difference in the lives of these local students and wish them success in the upcoming school year and beyond.

Thank you, Foundation Fighting Blindness, for all your work to develop resources for people living with Stargardt disease. Your support of research on Stargardt is leading the way toward potential treatments!

This week, we’re headed to the Genome Engineering: CRISPR Frontiers meeting at Cold Spring Harbor Laboratory. Join us for Dr. Nancy Craig's, Senior Vice President for Genetic Engineering, oral presentation about the precision of our Gene Coding™ technology and the high efficiency of our bioengineered transposase enzyme to integrate large genes into targeted sites. Her session begins at 9 a.m. EST on Friday, August 30. #cshlcrispr24

SalioGen is pleased to announce the appointment of Dr. Kali Stasi as Chief Medical Officer. Kali is a board-certified ophthalmologist with 30 years of experience in industry and academia, and a proven track record of advancing genetic medicines for retinal diseases from early- and late-stage clinical development through commercialization. In this position, Dr. Stasi will be responsible for bringing the company’s development candidate SGT-1001 into the clinic by mid-2025 as a one-time treatment for Stargardt disease and continuing to develop the company’s Gene Coding™ technology for other inherited retinal diseases and cystic fibrosis. Learn more: https://bit.ly/3YINyty

August is Children’s Eye Health & Safety Month, a time to raise awareness of the importance of taking care of children’s eyes and detecting vision problems early to optimize care. #Stargardt disease is an inherited form of macular degeneration causing central vision loss, often diagnosed in childhood or adolescence. Today, there is no treatment – but we are committed to changing that for patients and their families. Learn more about our research to develop potentially transformative new therapies for Stargardt and other inherited eye diseases: https://bit.ly/3X2e1Bk

Gene Coding™ technology simplifies the process of genetic medicine and will expand the range of treatable diseases by eliminating the need for viral vectors, cargo size constraints, and double-strand breaks. Check out our pipeline to see what’s on the horizon: https://bit.ly/3X2e1Bk

We are truly grateful for the opportunity to host Dr. Mike Marciello this week. His story about developing Stargardt disease later in life, adjusting to progressive vision loss, and actively supporting the community is a strong testament to the idea that anything is possible with determination. Thanks, Mike, for being an inspiration.

Saliogase™ transposase was created by Saliogen. It works by harnessing the power of natural enzymes, called transposases, to move DNA segments around the genome safely for evolutionary purposes. The Saliogase™ enzyme is based on a mammalian transposase that has evolved over thousands of years to adapt to the mammalian environment.

Gene Coding™ technology is powered by the Saliogase™ transposase, a proprietary enzyme derived from mammals and bioengineered by SalioGen scientists to seamlessly insert large pieces of DNA (up to 100 kb) into specific locations within the genome of targeted cells. Learn more: https://bit.ly/4dXzCRE